HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

Marisa Mariani; Mark McHugh; Marco Petrillo; Steven Sieber; Shiquan He; Mirko Andreoli; Zheyang Wu; Paul Fiedler; Giovanni Scambia; Shohreh Shahabi; Cristiano Ferlini

doi:10.18632/oncotarget.2049

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

Marisa Mariani, Mark McHugh, Marco Petrillo, Steven Sieber, Shiquan He, Mirko Andreoli, Zheyang Wu, Paul Fiedler, Giovanni Scambia, Shohreh Shahabi and Cristiano Ferlini _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:4855-4867. https://doi.org/10.18632/oncotarget.2049

Metrics: PDF 2929 views | HTML 4361 views | ?

Abstract

Marisa Mariani1,2, Mark McHugh1, Marco Petrillo2, Steven Sieber1, Shiquan He1, Mirko Andreoli1,2, Zheyang Wu3, Paul Fiedler1, Giovanni Scambia2,4, Shohreh Shahabi1,* and Cristiano Ferlini1,4,*

1 Danbury Hospital Research Institute, Danbury, CT, USA

2 Department of Gynecology, Catholic University of the Sacred Heart, Rome, Italy

3 Department of Mathematical Sciences, Worcester Polytechnic Institute, Worcester, MA, USA

4 Department of Oncology, Jean Paul IInd Research Foundation, Campobasso, Italy

* These Authors equally contributed to this work

Correspondence:

Cristiano Ferlini, email:

Keywords: HGF, Met, Ovarian Cancer

Received: March 31, 2014 Accepted: May 30, 2014 Published: June 1, 2014

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. Recently, NACT (Neo Adjuvant Chemotherapy) has been tested as alternative approach for the management of ovarian cancer patients. A biological predictor helpful in selecting patients for NACT would be desirable. This study was aimed at identifying actionable mechanisms of resistance to NACT.

Expression of a panel of microRNAs was screened in a discovery set of 85 patients. Analysis of the potential targets was conducted in the same RNAs by calculating significant correlations between microRNAs and genes. Quantitative fluorescent immunohistochemistry was employed in a validation set of 109 patients.

MiR-193a-5p was significantly overexpressed in the NACT setting. Analysis of its potential targets demonstrated that this microRNA is also significantly correlated with HGF and MET genes. Analysis of protein expression in samples taken before and after NACT demonstrated that both HGF and c-Met are increased after NACT. Patients who relapse shortly after NACT exhibited the highest relative basal expression of both HGF and c-Met, while the opposite phenomenon was observed in the best responders.

Mir-193a-5p, HGF and c-Met expression may help select eligible patients for this modality of treatment. Moreover, inhibitors of this pathway may improve the efficacy of NACT.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2049

Publication Alerts

Research Papers:

HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

Abstract